Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Burkitt Lymphoma 1

Interventions

pembrolizumab 312Carboplatin 159Nivolumab 159Cisplatin 141Cyclophosphamide 135Paclitaxel 129Magnetic Resonance Spectroscopy 99Specimen Handling 96Radiotherapy 94Gemcitabine 88Dexamethasone 86Biopsy 81Ipilimumab 81Docetaxel 78Doxorubicin 77Rituximab 71Etoposide 69Radiation 62durvalumab 62Lenalidomide 61atezolizumab 61Pemetrexed 59Prednisone 59Taxes 58Bevacizumab 55fludarabine 54olaparib 53Vincristine 52Cytarabine 51Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Medrol Veriderm × 1 year × Clear all
NCT00792948 2026-05-29

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
97 enrolled 7 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡